<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2016-02-25" updated="2019-12-02">
  <drugbank-id primary="true">DB11468</drugbank-id>
  <name>Tiamulin</name>
  <description>Tiamulin is a pleuromutilin antibiotic drug that is used in veterinary medicine particularly for pigs and poultry.</description>
  <cas-number>55297-95-5</cas-number>
  <unii>E38WZ4U54R</unii>
  <average-mass>493.742</average-mass>
  <monoisotopic-mass>493.322579687</monoisotopic-mass>
  <groups>
    <group>vet_approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A9007</ref-id>
        <pubmed-id>3686511</pubmed-id>
        <citation>Bouwkamp FT: [Tiamulin: a dangerous drug?]. Tijdschr Diergeneeskd. 1987 Nov 15;112(22):1295-6.</citation>
      </article>
      <article>
        <ref-id>A8609</ref-id>
        <pubmed-id>7233787</pubmed-id>
        <citation>Miller DJ: Monensin-tiamulin interaction. Vet Rec. 1981 Apr 4;108(14):317-8.</citation>
      </article>
      <article>
        <ref-id>A9008</ref-id>
        <pubmed-id>3952946</pubmed-id>
        <citation>Miller DJ, O'Connor JJ, Roberts NL: Tiamulin/salinomycin interactions in pigs. Vet Rec. 1986 Jan 18;118(3):73-5.</citation>
      </article>
      <article>
        <ref-id>A9009</ref-id>
        <pubmed-id>19060324</pubmed-id>
        <citation>Burch DG: Tiamulin activity against Brachyspira hyodysenteriae. Vet Rec. 2008 Dec 6;163(23):698; author reply 698.</citation>
      </article>
      <article>
        <ref-id>A9010</ref-id>
        <pubmed-id>7340095</pubmed-id>
        <citation>Pott JM, Shov B: Monensin--tiamulin interactions in pigs. Vet Rec. 1981 Dec 12;109(24):545.</citation>
      </article>
      <article>
        <ref-id>A9011</ref-id>
        <pubmed-id>19103625</pubmed-id>
        <citation>Burch DG: Tiamulin activity against Brachyspira hyodysenteriae. Vet Rec. 2008 Dec 20-27;163(25):760.</citation>
      </article>
      <article>
        <ref-id>A9012</ref-id>
        <pubmed-id>6854730</pubmed-id>
        <citation>Ziv G, Levisohn SL, Bar-Moshe B, Bor A, Soback S: Clinical pharmacology of tiamulin in ruminants. J Vet Pharmacol Ther. 1983 Mar;6(1):23-32.</citation>
      </article>
      <article>
        <ref-id>A9013</ref-id>
        <pubmed-id>6505670</pubmed-id>
        <citation>Wanner M: [Tiamulin and salinomycin intolerance in swine]. Schweiz Arch Tierheilkd. 1984 Oct;126(10):521-6.</citation>
      </article>
      <article>
        <ref-id>A9014</ref-id>
        <pubmed-id>7376381</pubmed-id>
        <citation>Horrox NE: Monensin-tiamulin interaction risk to poultry. Vet Rec. 1980 Mar 22;106(12):278.</citation>
      </article>
      <article>
        <ref-id>A9015</ref-id>
        <pubmed-id>21511410</pubmed-id>
        <citation>Rubin JE, Ball KR, Chirino-Trejo M: Decreased susceptibility of MRSA ST398 to tiamulin. Vet Microbiol. 2011 Aug 5;151(3-4):422-3. doi: 10.1016/j.vetmic.2011.03.030. Epub 2011 Apr 1.</citation>
      </article>
      <article>
        <ref-id>A9016</ref-id>
        <pubmed-id>15013817</pubmed-id>
        <citation>Szucs G, Tamasi V, Laczay P, Monostory K: Biochemical background of toxic interaction between tiamulin and monensin. Chem Biol Interact. 2004 Mar 15;147(2):151-61.</citation>
      </article>
      <article>
        <ref-id>A9017</ref-id>
        <pubmed-id>16253666</pubmed-id>
        <citation>Pringle M, Landen A, Franklin A: Tiamulin resistance in porcine Brachyspira pilosicoli isolates. Res Vet Sci. 2006 Feb;80(1):1-4. Epub 2005 Apr 2.</citation>
      </article>
      <article>
        <ref-id>A9018</ref-id>
        <pubmed-id>25592328</pubmed-id>
        <citation>De Baere S, Devreese M, Maes A, De Backer P, Croubels S: Quantification of 8-alpha-hydroxy-mutilin as marker residue for tiamulin in rabbit tissues by high-performance liquid chromatography-mass spectrometry. Anal Bioanal Chem. 2015 Jun;407(15):4437-45. doi: 10.1007/s00216-014-8437-9. Epub 2015 Jan 16.</citation>
      </article>
      <article>
        <ref-id>A9019</ref-id>
        <pubmed-id>3170319</pubmed-id>
        <citation>Ross RF, Cox DF: Evaluation of tiamulin for treatment of mycoplasmal pneumonia in swine. J Am Vet Med Assoc. 1988 Aug 15;193(4):441-6.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication/>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as pleuromutilin and derivatives. These are mutilins with a hydroxyacetate derivative attached to the C8 carbon atom of the cyclopenta[8]annulene moiety.</description>
    <direct-parent>Pleuromutilin and derivatives</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Lipids and lipid-like molecules</superclass>
    <class>Prenol lipids</class>
    <subclass>Diterpenoids</subclass>
    <alternative-parent>Amino acids and derivatives</alternative-parent>
    <alternative-parent>Carboxylic acid esters</alternative-parent>
    <alternative-parent>Dialkylthioethers</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Ketones</alternative-parent>
    <alternative-parent>Monocarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Secondary alcohols</alternative-parent>
    <alternative-parent>Sulfenyl compounds</alternative-parent>
    <alternative-parent>Trialkylamines</alternative-parent>
    <substituent>Alcohol</substituent>
    <substituent>Aliphatic homopolycyclic compound</substituent>
    <substituent>Amine</substituent>
    <substituent>Amino acid or derivatives</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Carboxylic acid ester</substituent>
    <substituent>Dialkylthioether</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Ketone</substituent>
    <substituent>Monocarboxylic acid or derivatives</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Organosulfur compound</substituent>
    <substituent>Pleuromutilin</substituent>
    <substituent>Secondary alcohol</substituent>
    <substituent>Sulfenyl compound</substituent>
    <substituent>Tertiary aliphatic amine</substituent>
    <substituent>Tertiary amine</substituent>
    <substituent>Thioether</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001660</drugbank-id>
      <name>Tiamulin hydrogen fumarate</name>
      <unii>ION1Q02ZCX</unii>
      <cas-number>55297-96-6</cas-number>
      <inchikey>YXQXDXAHCSEVSD-GCYNEOGWSA-N</inchikey>
      <average-mass>609.82</average-mass>
      <monoisotopic-mass>609.33353878</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="inn">Tiamulin</synonym>
    <synonym language="spanish" coder="inn">Tiamulina</synonym>
    <synonym language="french" coder="inn">Tiamuline</synonym>
    <synonym language="latin" coder="inn">Tiamulinum</synonym>
  </synonyms>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Anti-Bacterial Agents</category>
      <mesh-id>D000900</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Terpenes</category>
      <mesh-id>D013729</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>1xbp</pdb-entry>
    <pdb-entry>3g4s</pdb-entry>
  </pdb-entries>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB09268</drugbank-id>
      <name>Picosulfuric acid</name>
      <description>The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Tiamulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12768</drugbank-id>
      <name>BCG vaccine</name>
      <description>The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Tiamulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14022</drugbank-id>
      <name>Typhoid vaccine</name>
      <description>The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Tiamulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>The risk or severity of bleeding can be increased when Tiamulin is combined with Dicoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>The risk or severity of bleeding can be increased when Tiamulin is combined with Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>The risk or severity of bleeding can be increased when Tiamulin is combined with Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>The risk or severity of bleeding can be increased when Tiamulin is combined with Phenprocoumon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The risk or severity of bleeding can be increased when Tiamulin is combined with Acenocoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03410</drugbank-id>
      <name>4-hydroxycoumarin</name>
      <description>The risk or severity of bleeding can be increased when Tiamulin is combined with 4-hydroxycoumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04665</drugbank-id>
      <name>Coumarin</name>
      <description>The risk or severity of bleeding can be increased when Tiamulin is combined with Coumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The risk or severity of bleeding can be increased when Tiamulin is combined with (R)-warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>The risk or severity of bleeding can be increased when Tiamulin is combined with Ethyl biscoumacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>The risk or severity of bleeding can be increased when Tiamulin is combined with Fluindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13275</drugbank-id>
      <name>Clorindione</name>
      <description>The risk or severity of bleeding can be increased when Tiamulin is combined with Clorindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13347</drugbank-id>
      <name>Diphenadione</name>
      <description>The risk or severity of bleeding can be increased when Tiamulin is combined with Diphenadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13451</drugbank-id>
      <name>Tioclomarol</name>
      <description>The risk or severity of bleeding can be increased when Tiamulin is combined with Tioclomarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>The risk or severity of bleeding can be increased when Tiamulin is combined with (S)-Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00581</drugbank-id>
      <name>Lactulose</name>
      <description>The therapeutic efficacy of Lactulose can be decreased when used in combination with Tiamulin.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>4.47</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>5.24e-04 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>4.5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxotricyclo[5.4.3.0^{1,8}]tetradecan-6-yl 2-{[2-(diethylamino)ethyl]sulfanyl}acetate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxotricyclo[5.4.3.0^{1,8}]tetradecan-6-yl 2-{[2-(diethylamino)ethyl]sulfanyl}acetate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>493.742</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>493.322579687</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[H][C@@]12C(=O)CC[C@]11CC[C@@]([H])(C)[C@@]2(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]1C)OC(=O)CSCCN(CC)CC</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C28H47NO4S</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C28H47NO4S/c1-8-26(6)17-22(33-23(31)18-34-16-15-29(9-2)10-3)27(7)19(4)11-13-28(20(5)25(26)32)14-12-21(30)24(27)28/h8,19-20,22,24-25,32H,1,9-18H2,2-7H3/t19-,20+,22-,24+,25+,26-,27+,28+/m1/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>UURAUHCOJAIIRQ-QGLSALSOSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>66.84</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>140.74</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>57.98</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>10</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>14.43</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>9.51</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>28</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>44137</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C12065</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D06127</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>571196</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>MUL</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Tiamulin</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1234521</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>